Inspra (Eplerenone)

Eplerenone selectively blocks mineralocorticoid receptors, preventing aldosterone from promoting sodium reabsorption and potassium loss in the kidneys. This leads to increased excretion of sodium and water, reduced blood volume, lower blood pressure, and less cardiac remodeling in heart‑failure patients.

The appropriate dose of Inspra is determined by a qualified prescriber based on the individual’s medical condition, kidney function, and potassium levels. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the dose without medical advice.

The safety of eplerenone during pregnancy or lactation has not been fully established. Healthcare providers usually weigh potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss any concerns with their doctor.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Inspra (eplerenone) is more selective for the mineralocorticoid receptor than some alternatives, such as spironolactone, which can cause hormonal side effects like gynecomastia. This selectivity often results in a lower incidence of endocrine‑related adverse events while providing similar cardiovascular benefits.

Inspra should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Inspra is taken orally, usually as a tablet, with or without food as directed by a healthcare professional. The exact timing and frequency depend on the prescribed regimen, and patients should swallow the tablet whole with a glass of water.

The most serious risks include hyperkalemia, which can lead to dangerous heart rhythm disturbances, and acute kidney injury. Patients should have regular monitoring of serum potassium and renal function, especially when starting therapy or adjusting doses.

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, severe renal impairment, or significant hyperkalemia. It should also be avoided in patients taking other potent potassium‑sparing agents unless closely supervised by a physician.